The Basque biotechnology company, Progenika Biopharma, devoted to research and development in personalised medicine, have presented a DNA biochip, known as BLOODchip, which greatly eliminates the risk of adverse reactions due to incompatibility in blood groups between donor and receptor in blood transfusions.

With the aim of guaranteeing safety during blood transfusions, Progenika has developed and validated 1,000 clinical samples in cooperation with the principal European blood banks. Concretely, the validation of these samples was 99.8%, considerably higher than that produced using the current serology technique, which produces an error of 3%.

Thus, BLOODchip is currently the safest and most precise technique for genetically determining blood groups, enabling the reduction of adverse reactions in blood transfusions.

Two different techniques are currently used to detect possible incompatibilities in blood transfusions: the serological method and DNA sequencing. The serological technique has a limited capacity and does not allow the detection of 3% of the incompatibilities existing. DNA sequencing, while overcoming this drawback of the serological method, is however a slow and costly system.

Progenika has developed BLOODchip to respond to the disadvantages of the current systems. In this way, the totality of blood group incompatibilities are detected in a safer, quicker and more specific analytical process than with the serological technique. Moreover, its cost is twenty times less than DNA sequencing, which enables its generalized and routine use in all blood transfusions.

The BLOODchip is the result of research within the remit of the European Union IV Framework Programme and undertaken by Progenika in collaboration with the principal European blood banks.

It should be pointed out that Progenika Biopharma has developed and patented various products that are already on the market for several types of di
'"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
4-Jul-2007